Bioelectronics Corp (BIEL)

[chado]

Issues with Economic Study:

1. Only a 30 Person Test.
2. Only a 3-month Test.
3. Only done in the UK.

This is a TERRIBLE representation of the general population of pain users.
For one, the number of test subjects needs to be DRASTICALLY HIGHER. For second, it needs to span multiple age brackets, and multiple types of subjects with varying healthcare coverage / prescription coverage. Third, a small test in the UK doesn't mean a hill of beans to the USA population.

Can't BIEL do any better than a less than half-ass economic test. That was a FLUFF PR at it's worst. Pure FLUFF.

As a said earlier, it is likely "directionally" correct to say actipatch provides a net cost reduction...BUT, this test in NO WAY provides credibility to such an assumption because it was a poorly thought out test, nowhere near an accurate represention of the overall pain user population. 41% savings is likely a HUGE EMBELISHMENT...Even if it was a 10% savings, that 10% is still a GOOD savings. Why can't BIEL conduct a better test with more credible and believable results.